Tramadol/acetaminophen fixed-dose combination tablets (Tramse) combine tramadol, a centrally acting week opioid analgesic, with low-dose acetaminophen. The action of tramadol may be described as a weak agonist at the mu-opioid receptor, inhibition of serotonin reuptake, and inhibition of noradrenaline reuptake. The second component in these tablets, acetaminophen mainly appears to act through central mechanism. Chronic pain may be broadly classified into nociceptive, neuropathic and mixed. Tramset may exert additive or synergic benefits in treating the multiple mechanism of pain. Clinical studies have revealed its efficacy and safety for a variety of pain condition such as chronic low back pain, rheumatoid arthritis, fibromyalgia and painful diabetic peripheral neuropathy. It is expected that Tramset is going to induce pain relief and to improve disturbance of daily life in patients with intractable chronic pain. However overuse of Tramset may induce severe adverse effects such as addiction, abuse and hepatotoxicity. Therefore clinician should continuously assess pain intensity, activity of daily life, mode of its consumption, and adverse effects after prescription.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Polysaccharides isolated from Cibotium barometz attenuate chronic inflammatory pain: Molecular chemical structure and role of phenylalanine.
Int J Biol Macromol
January 2025
Department of Pain Management, Qilu Hospital of Shandong University, 107# West Wenhua Road, Jinan, Shandong 250012, China. Electronic address:
This investigation represents a pioneering effort to examine the therapeutic effects of PCB specifically in the context of CFA-induced mice, as well as to elucidate the underlying mechanisms that facilitate such effects. Our study utilized advanced methodologies, namely high-performance liquid chromatography coupled with mass spectrometry (HPLC-MS)-based metabolomics, alongside comprehensive multivariate data analysis, to identify a distinctive metabolic profile associated with acute inflammation. Through our analyses, we discovered that several potential metabolites were significantly implicated in a variety of critical metabolic pathways.
View Article and Find Full Text PDFChronic Low Back Pain Causal Risk Factors Identified by Mendelian Randomization: a Cross-Sectional Cohort Analysis.
Spine J
January 2025
Department of Orthopaedic Surgery, University of California, San Francisco.
Background Context: There are a number of risk factors- from biological, psychological, and social domains- for non-specific chronic low back pain (cLBP). Many cLBP treatments target risk factors on the assumption that the targeted factor is not just associated with cLBP but is also a cause (i.e, a causal risk factor).
View Article and Find Full Text PDFHistamine H receptor blockade alleviates neuropathic pain through the regulation of glial cells activation.
Biomed Pharmacother
January 2025
Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Neurochemistry, 12 Smetna Str., Krakow 31-343, Poland. Electronic address:
Neuropathic pain is a disorder affecting the somatosensory nervous system. However, this condition is also characterized by significant neuroinflammation, primarily involving CNS-resident non-neuronal cells. A promising target for developing new analgesics is histamine H receptor (HR); thus, we aimed to determine the influence of a novel HR antagonist/inverse agonist, E-98 (1-(7-(4-chlorophenoxy)heptyl)-3-methylpiperidine), on pain symptoms and glia activation in model of neuropathic pain in male mice (chronic constriction injury to the sciatic nerve).
View Article and Find Full Text PDFChronic pain and comorbid posttraumatic stress disorder: Potential mechanisms, conceptualizations, and interventions.
Curr Opin Psychol
January 2025
Department of Psychology, University of Southern Denmark, Odense, Denmark; Specialized Hospital for Polio and Accident Victims, Rødovre, Denmark.
Posttraumatic stress disorder (PTSD) is a common comorbidity to chronic pain, among others due to potentially shared posttraumatic origin. There has been growing interest in this field in the past decades, also providing some important studies to support our understanding of this comorbidity and how to address it in clinical practice. However, there are still important questions, particularly regarding the potentially shared vulnerabilities, mutually maintaining mechanisms, and how to best treat this comorbidity.
View Article and Find Full Text PDFPain severity contributes to worse outcomes in opioid use disorder recovery than pain status.
Drug Alcohol Depend
January 2025
Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States.
Background: Opioid use disorder (OUD) continues to pose a significant challenge to public health in the United States. Chronic pain and OUD are highly comorbid conditions, yet few studies have examined the relative associations of pain status and severity toward multidimensional OUD recovery outcomes (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!